北大医药股价涨5.82%，广发基金旗下1只基金位居十大流通股东，持有227.8万股浮盈赚取77.45万元

Group 1 - The core viewpoint of the news is that Beida Pharmaceutical's stock has increased by 5.82%, reaching a price of 6.18 yuan per share, with a total market capitalization of 3.683 billion yuan as of the report date [1] - Beida Pharmaceutical Co., Ltd. is located in Chongqing and was established on May 18, 1993, with its listing date on June 16, 1997. The company focuses on the research, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services [1] - The main business revenue composition of Beida Pharmaceutical includes: pharmaceuticals 34.69%, formulation drugs 34.34%, medical devices and reagents 30.82%, other (supplement) 0.13%, and sales of goods and materials 0.03% [1] Group 2 - From the perspective of the top ten circulating shareholders, one fund under GF Fund ranks among the top shareholders of Beida Pharmaceutical. The fund, GF Quantitative Multi-Factor Mixed A (005225), newly entered the top ten shareholders in the third quarter, holding 2.278 million shares, accounting for 0.38% of the circulating shares [2] - The GF Quantitative Multi-Factor Mixed A fund was established on March 21, 2018, with a latest scale of 3.618 billion yuan. It has achieved a return of 42.25% this year, ranking 869 out of 8209 in its category [2] - The fund managers, Yi Wei and Li Yuxin, have had notable performance during their tenure, with Yi Wei achieving a best fund return of 59.46% and Li Yuxin achieving a best fund return of 81.47% [2]